CERTALDO (FLORENCE), Italy–(BUSINESS WIRE)–The growth of the Italian medical device start-up Endostart continues with the appointment of Christopher Rowland, a global medical device industry expert, as Chairman of the Company’s Board of Directors.
With more than 30 years of experience in positions of increasing responsibility in sales, product development, marketing, business development, and CEO leadership in the United States and abroad, Chris brings experience and unparalleled skills in a wide variety of vertical clinical and commercial medical devices including gastroenterology, cardiology, urology, radiology and peripheral vascular specialties.
His professional experience includes 17 years at Boston Scientific, ending as Global Vice President of Marketing for the Endoscopy Division; he was also President of Given Imaging Inc. (acquired by Covidien/MDT) and President/CEO of Neotract Inc. (acquired by Teleflex). Chris is also currently President and CEO of Tricol Biomedical, a leader in hemostasis technology.
In his new role, Chris will work with and coordinate the Endostart Board of Directors.
“With his long history of leadership and expertise in the digestive endoscopy industry, Chris is the ideal Chairman of the Board for Endostart,” said Alessandro Tozzi, CEO and Founder of Endostart. “We are sure that Chris will be a driving force in our success.”
“I am delighted to support the investors and the management team of this dynamic company. I believe Endostart is poised for significant growth reflecting demand for its innovative products to improve endoscopic performance,” said Rowland. “I look forward to helping Endostart maximize shareholder value and realize its business potential.”
Endostart’s first product is Endorail™, an innovative medical device to facilitate the performance of colonoscopy procedures using magnetic balloon technology. This technology is designed to improve endoscope performance and allow endoscopists to easily achieve quality standards. Endorail received CE Mark in 2019 and has been clinically tested. It is not yet cleared by the US Food and Drug Administration (FDA).
Founded in 2018, Endostart focuses on developing and manufacturing next-generation medical devices for gastrointestinal endoscopy. The company is ISO 13485 certified. It has an international board of directors and a strong medical advisory board. It recently announced a capital increase of 8.2 million euros (10 million US dollars).